BRVE (Braveheart Bio Inc.) stock: $18.60, $1.67B market cap, $474.0M cash, $1.20B EV, $1.89B fully diluted market cap. Next expected readout: Oct-28. Lead program: BHB-1893 (Cardiomyopathy, Hypertrophic Obstructive), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
The Company is a clinical-stage biopharmaceutical company dedicated to developing therapeutics to treat hypertrophic cardiomyopathy (“HCM”) and related conditions by targeting overactive proteins within the heart.
Primary: Long-term efficacy and safety in the 52-week open-label extension of the Phase 2 study in obstructive hypertrophic cardiomyopathy: exercise capacity (peak oxygen uptake, pVO2), patient-reported outcomes (KCCQ-CSS), and Valsalva left ventricular outflow tract gradient (LVOT-G) — At Week 52, peak oxygen uptake (pVO2) increased by a mean of 2.7 mL/kg/min from OLE baseline; Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) increased by a mean of 17.3 points over the same period; 79% (33/42) of patients achieved a Valsalva LVOT gradient (LVOT-G) below 30 mmHg
· All 42 patients restarted HRS/BHB-1893 for an additional 52 weeks in the OLE after the 12-week core period and a washout period
· 70% of patients achieving a ≥1.5 mL/kg/min improvement in pVO2 and 50% achieving a ≥3.0 mL/kg/min improvement at Week 52
· 45% of patients achieving a ≥20-point improvement in KCCQ-CSS at Week 52
· 60% of patients achieved New York Heart Association (NYHA) Class I after 52 weeks of treatment
· 90% of patients achieving a Valsalva gradient <30 mmHg at one or more visits during the treatment period
· 57% of patients (24/42) were maintained on the 40 mg twice-daily (BID) starting dose, and an additional 19% (8/42) were maintained on 60 mg BID at end of study
Safety: Generally well tolerated across the 52-week OLE period, with no on-treatment severe or serious adverse events; all on-treatment treatment-emergent adverse events were mild or moderate, no adverse events led to permanent study drug discontinuation, and two patients had transient reductions in LVEF below 50% (48% and 49% site-measured) and resumed treatment at a lower dose
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead product candidate; LIONHEART-HCM Phase 3 trial initiated in oHCM; global Phase 3 development planned in oHCM and nHCM. IPO completed Aug 7, 2026 ($404.5M net proceeds).
Per-asset detail extracted from the 10-Q filed 2026-09-08. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.